Barely Significant
← all excerpts

Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer.

J Immunother Cancer · 2025 · PMC11865721 · PMID 40010771

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

nominally significantp≤0.05actually significant
18 Nevertheless, considering the sample size limitations, throughout the manuscript we show nominally significant results as p≤0.05 and results significant after adjustment for multiple testing as FDR≤0.05.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.